Introduction
In 1897, Felix Hoffman of the Bayer company first synthesized acetylsalicylic acid. Aspirin as a trade name of acetylsalicylic acid became commercially available in 1899. Since then, aspirin has commonly been prescribed as an antipyretic analgesic agent. In 1953, the antithrombotic effects of aspirin were initially reported. 1 In 1967, the antiplatelet actions of aspirin were found. 2 In 1971, Smith and Willis 3 and Vane 4 independently proposed that the action mechanism of aspirin involves inhibition of cyclooxygenase 1 (COX-1). In addition, in 1991, Funk et al. 5 found aspirin-related acetylation and inactivation of the active site of COX-1, Ser at position 529. In platelets, aspirin inhibits production of a potent platelet-aggregating substance, thromboxane A 2 (TXA 2 ), via inhibition of COX-1, suppressing platelet aggregation. Based on this pharmacologic action, a large-scale clinical trial demonstrated the preventive effects of aspirin on recurrent ischemic heart disease and cerebral infarction. In meta-analysis by Antithrombotic Trialists' Collaboration, the incidence of vascular events, including nonfatal myocardial/cerebral infarction and vascular event-related death, in approximately 60 000 patients taking aspirin was 25% lower than that in controls. 6 Furthermore, there were individual differences in the antiplatelet effects of aspirin: inhibition of thrombus formation, prolongation of the bleeding time, inhibition of platelet aggregation ex vivo and inhibition of thromboxane production in platelets. The entity of 'aspirin resistance', which represents a state in which aspirin is not effective or less effective, was proposed. Eikelboom et al. 7 performed 4.5-year follow-up of 976 patients undergoing aspirin therapy, and reported an association between urinary excretion of a TXA 2 metabolite and cardiovascular events. Gum et al. 8 administered aspirin to 326 patients with coronary disease or cerebral infarction, and investigated the relationship between platelet aggregation and the development of cardiovascular events. In an aspirin-resistant group in which platelet aggregation was not inhibited, the hazard ratio of cardiovascular events was 4.1 times higher than that in an aspirin-sensitive group.
Quinn et al. 9 have indicated that, in approximately 30% of patients with differences in the platelet responsiveness to antiplatelet agents, it is associated with heredity, suggesting the importance of genetic polymorphism. Concerning platelet membrane glycoproteins, it has been reported that genetic polymorphisms of GPIa, 10 GPIba, 11 GPIIIa 12,13 and GPVI 14 influence the efficacy of aspirin or platelet responsiveness. Furthermore, Halushka et al. 15 reported the association of platelet aggregation with genetic mutation of COX-1, Papafili et al. 16 the association with genetic mutation of COX-2, Higuchi et al. 17 the association with genetic mutation of TXA 2 receptors (TP), Stafforini et al. 18 the association with genetic mutation of platelet activating factor acetylhydrolase (PAFAH) and Undas et al. 19 the association with genetic mutation of coagulation factor XIII (FXIII).
Thus, many studies have investigated the platelet responsiveness to aspirin in Caucasians at the gene level. However, few studies have reported this issue in Japanese patients or healthy volunteers. In this study, we focused on the arachidonic acid cascade and genes involved in platelet aggregation, and evaluated the aspirin resistance in Japanese based on the suppressive degree of platelet aggregation before and after aspirin administration. Here, the low suppressive degree of platelet aggregation after aspirin administration was defined as aspirin resistance.
This study was designed by the Japan Pharmacogenomics (JPG) Consortium. This organization consists of 11 pharmaceutical-related companies in Japan. From July 2003 to July 2005, these companies collaboratively arranged environments, and established basic techniques for pharmacogenomics (PG) studies in Japan to promote the research and development of agents in Japan. Recently, it has been proposed that data on PG should be submitted to the authorities concerned with medicinal development in Japan, the United States and Europe. In the future, PG studies may lead to individualized medical practices, that is, the essential target of medical practice, 'a necessary agent at a required dose is administered to patients requiring it for a required period'.
Results

Patient background
The subjects were 110 healthy male adult Japanese volunteers (26. 976.3-year-old (mean7s.d., minimum: 20, maximum: 45 years)). Normal health status was determined at the beginning of this study by medical history, physical examination and biochemical and hematological screening. In two of the subjects, this study was not completed, and parameters other than the frequency of alleles were investigated in 108 subjects. The background factors of the subjects are shown in Table 1 . No subject showed any abnormal value of body mass index(21.672.4 kg/m 2 (minimum: 16.5, maximum: 27.2)). The hematological and biochemical data were within the normal ranges. There were no abnormalities in the blood total cholesterol or triglyceride levels, which may influence platelet aggregation and the bleeding time; the mean values were 170728 and 89756 mg/dl, respectively. We examined the presence or absence of a smoking history; 44 subjects had a history, but 64 subjects did not.
Frequency of alleles
In the 110 subjects, we performed genotyping of 24 singlenucleotide polymorphisms (SNPs), which are present in nine genes, COX-1 (PTGS1), COX-2 (PTGS2), TP (TBXA2R), GPIa (ITGA2), GPIba (GP1BA), GPIIIa (ITGB3), GPVI (GP6), FXIII (F13A) and PAFAH, which may be related to platelet responsiveness, and calculated the frequency of alleles (Table 2 ). In nine of the 24 SNPs, the frequency of minor alleles exceeded 10%. The 24 SNPs suited the HardyWeinberg equilibrium. The frequency of alleles is shown in Table 2 Figure 1 shows the maximum aggregation (%) before and after administration of aspirin with respect to the collagen levels.
To examine the effects of aspirin, the maximum aggregation (%) before and after aspirin administration at a collagen level of 1.0 or 4.0 mg/ml, the ratio of change in the maximum aggregation (%) between before and after aspirin administration, the area under the curve (AUC) for the maximum aggregation at collagen levels ranging from 0 to 4.0 mg/ml before and after aspirin administration, and the ratio of change in the AUC between before and after aspirin administration were determined, and these parameters were compared in each SNP group. The maximum aggregation at collagen levels of 1.0 and 4.0 mg/ml was suppressed by about 83% (81.9 to 13.6%) and 41% (90.8 to 53.9%), respectively, by aspirin administration. Furthermore, the AUC after administration was lower than that before administration, and the rate of decrease was about 44% (before administration: 309729 arbitrary unit (AU) vs after administration: 174744 AU, Po0.0001).
We analyzed the association between platelet aggregation and SNPs by Student's t-test or analysis of variance (ANOVA). TP 924T4C and GPIba 1018C4T showed significant differences. Figure 2 shows the structures of TP and GPIba proteins and the positions of SNPs.
Relationship between platelet aggregation and TP 924T4C. Concerning TP SNP (924T4C), there were significant differences in the rate of change in the maximum aggregation at collagen levels of 1.0 and 4.0 mg/ml between the two groups (TT group vs TC þ CC group); in the TT group, the values were higher (P ¼ 0.0076 and 0.0121, respectively). In the TT group, the values were low before aspirin administration and high after aspirin administration (Figures 3a and b) . In addition, there were significant differences in the rate of change in the AUC between the two groups; in the TT group, the value was higher (P ¼ 0.0059) (Figures 3c). These results suggest the involvement of the TT group in aspirin resistance. There was a linkage disequilibrium between TP 795T4C and TP 924T4C. Concerning 795T4C, similar results were obtained (data not shown).
Relationship between platelet aggregation and GPIba 1018C4T. Concerning GPIba SNP, 1018C4T, there was a significant difference in the rate of change in the maximum aggregation at a collagen level of 4.0 mg/ml between the two groups (CC group vs CT þ TT group); the value was higher in the CC group (P ¼ 0.0130) (Figure 4b ). In the CC group, the value was high after aspirin administration (P ¼ 0.0044). Furthermore, there was a significant difference in the rate of change in the AUC between the two groups; in the CC group, the value was higher (P ¼ 0.0418) (Figure 4c ). These results suggest that the CC group in GPIba 1018C4T is involved in aspirin resistance.
Relationship of the combination of TP 924T4C and GPIba 1018C4T genotypes to platelet aggregation. To investigate the effects of genotype combination, we performed ANOVA and the Tukey's honestly significant difference (Tukey's HSD) test among subgroups in which a TP 924T4C genotype was combined with a GPIba 1018C4T genotype. In the ANOVA analysis, there were significant differences in the rate of change in the maximum aggregation at collagen levels of 1.0 and 4.0 mg/ml and the rate of change in the AUC among the four groups, 1:924TT and 1018CC (n ¼ 69), 2: 924TT and 1018CT þ TT (n ¼ 7), 3: 924TC þ CC and 1018CC (n ¼ 26) and 4: 924TC þ CC and 1018CT þ TT (n ¼ 6)(P ¼ 0.0282, 0.0109 and 0.0078, respectively) ( Figure  5 ). The TP TT and GPIba CC groups showed the highest rate of change in the maximum aggregation at a collagen level of 4.0 mg/ml, and the rate of change in the AUC. The TP TC þ CC and GPIba CT þ TT groups showed the lowest values; there were significant differences between group 1 and group 4 (P ¼ 0.0325 and 0.0092, respectively) in the Tukey's HSD test.
Serum level of thromboxane B 2
The serum levels of thromboxane B 2 (TXB 2 ) before and after administration of aspirin were 103 470769 007 pg/ml and 1987152 pg/ml, respectively; in all subjects, the rate of decrease was 98% or more. Therefore, aspirin almost completely inhibited production of TXA 2 .
Blood levels of aspirin and salicylic acid The blood level of aspirin reached a maximum (Cmax) (1.3870.65 mg/ml) 15 min after administration. The half-life was 22 min. The blood level of salicylic acid increased with aspirin metabolism, and reached a Cmax (5.0671.08 mg/ml) 60 min after administration.
Association
We examined associations among the maximum aggregation, TXB 2 level, maximum blood aspirin level (Cmax) and Cmax of salicylic acid. There was no association in any combination (data not shown).
Discussion
COX-1 is the first enzyme, in the arachidonic acid cascade, that catalyzes production of prostaglandins and thromboxanes from arachidonic acid. Aspirin reduces production of TXA 2 by irreversibly inhibiting platelet COX-1. According to a study, 15 the frequency of minor alleles in COX-1 SNPs (À842G, 50T) in Caucasians is 10.5 and 8.6%, respectively, suggesting that these SNPs are associated with aspirin resistance in Caucasians. In this study, we initially analyzed the frequency of alleles in five SNPs of COX-1 in Japanese subjects. However, no minor allele was detected in either of the above two SNPs. Therefore, the two COX-1 SNPs may not be involved in the effects of aspirin in Japanese people. In Caucasians, the frequency of minor alleles in COX-2 SNP (À765G4C) in the promoter region was 21.3%; however, in this study, the percentage was markedly lower (1.8%). A study has reported that À765G4C is involved in promoter activity. 16 However, the frequency of alleles was markedly low in our Japanese subjects; therefore, COX-2 may not be involved in aspirin resistance, as demonstrated for COX-1. In Caucasians, the frequency of minor alleles in FXIII SNP (100G4T), which may contribute to activation of FXIII, 19 was 22.1%; however, in this study, there was no minor allele.
In this study, the frequency of alleles in GPIIIa SNP (1565T4C) was 0.5%. A study has reported that this type of SNP is a risk factor for acute coronary disease, suggesting the association with aspirin resistance. 20 In Caucasians, many studies have indicated that COX-1, COX-2, FXIII and GPIIIa SNPs are associated with platelet aggregation or the bleeding time, suggesting the association with aspirin resistance. However, in this study, the frequency of minor alleles in these SNPs was markedly lower than that in Caucasians; these SNPs may not be associated with aspirin resistance in Japanese people.
When the vascular endothelium is damaged, GPIba plays an important role in the initial process of platelet aggregation by forming a complex in combination with GPIX and GPV and binding to von Willebrand factor (vWF). GPIba 1018C4T induces amino-acid substitution (T145M) via non-synonymous mutation. However, a study reported that 145Thr and 145Met recombinant proteins showed similar vWF binding activity in vitro, and that there was no functional difference. 21 The Leu-rich region is present around the site of this SNP, and may be involved in binding to proteins, such as GPIX, GPV and thrombin. Therefore, this SNP may affect the function of this region, there may be a linkage disequilibrium with the functional SNP(s), or this SNP may influence the degree of GPIba transcription and translation.
In this study, there was an association between the TP 924T4C genotype and the platelet responsiveness to aspirin. 924T4C reflects a synonymous mutation. This type of mutation does not directly influence receptor function; however, as the involvement in aspirin resistance was suggested, 924T4C may affect mRNA stabilization and translation efficiency, or there may be a linkage disequilibrium in a mutation associated with the function adjacent to this SNP. Immediately downstream of the SNP site, the site of alternative splicing is present, and a-type receptor and b-type receptor appear via splicing. There were no marked differences in TXA 2 ligand binding activity or phospholipase C activation between the two receptors. However, a-type activates adenyl cyclase, but b-type inhibits the activity. 22 This SNP may influence the splicing. In this study, aspirin administration markedly inhibited platelet TXA 2 production in all subjects. However, there were individual differences in the inhibitory effects of aspirin on collagen aggregation. Therefore, TP-related aspirin resistance may occur by:
(1) The hypersensitivity of TP to the extremely low levels of TXA 2 ; (2) Concerning the influence on TP, isoprostan, which is non-enzymatically synthesized via an O 2 radical response from arachidonic acid accumulating via the inhibition of platelet COX-1, may be involved as an alternate pathway other than TXA 2 ; isoprostan may bind to TP, activating the route. However, individual differences in isoprostan accumulation may be associated with aspirin resistance. 23 Furthermore, platelets are activated via several receptors including TP. Platelet activation by activating factors other than TXA 2 , such as thrombin, ADP, epinephrine and collagen, may reduce the effects of aspirin, leading to aspirin resistance. In this study, we found that two SNPs were associated with the platelet responsiveness to aspirin. We analyzed the combination of the genotypes of the two SNPs. There was an additive effect between aspirin resistance and amount of TP 924T and GPIba 1018C alleles. Therefore, the two SNPs may induce aspirin resistance via individual routs.
In addition, a high blood level of aspirin is considered to be an etiological factor involved in aspirin resistance; therefore, we measured the levels of aspirin and its metabolite after administration of aspirin. These levels were not associated with platelet aggregation; a decrease in the blood level of aspirin may not reflect aspirin resistance.
Previous studies have reported that aspirin resistance occurred in 5.5-56.8% of the patients in various patient groups. 24 In treatment for the suppression of recurrence in patients with ischemic heart diseases or cerebral infarction in the stable stage, the diagnosis of aspirin resistance is clinically important. Association analysis between genotype and phenotype with candidate genes including the SNPs detected in this study in patients with such diseases in the stable stage will help identify valid markers of aspirin resistance.
Materials and methods
Study design
In this open study, we administered 81 mg of plain aspirin (Nakakita Co. Ltd., Nagoya, Japan) to healthy male adult Japanese volunteers once a day for 7 days. They took this agent in the ward on Days 1 and 7, and at home on Days 2-6. On Day 1, blood samples for measuring platelet aggregation and thromboxane production were collected, and the subjects took one tablet of aspirin after having a light meal. Between Days 2 and 6, they took one tablet of aspirin with 150 ml of water after breakfast. On Day 7, this agent was administered after fasting. To measure the levels of aspirin and salicylic acid, blood was collected immediately before administration and 15, 30, 45, 60 and 75 min after administration. In addition, blood was collected to determine platelet aggregation and thromboxane production 60 min after administration.
Subjects
Among the persons registered in the trial volunteer panel managed by Maruyama Hospital, the subjects were 110 volunteers from whom written informed consent was obtained and who were considered to be eligible by the principal investigator or co-investigators based on the screening findings. We excluded persons with drug hypersensitivity, those with a history of aspirin-related asthma, those with bleeding tendency, and those who had taken agents including OTC drugs within 2 weeks before administration of the test agent. The hematological and biochemical parameters were within the normal ranges. This study was approved by the Trial Review Board and Ethical Review Board in the hospital participating in this study, and performed in accordance with the Declaration of Helsinki Principle. To improve compliance at home, a newly designed electronic monitoring device 25 was employed. There was no residual drug or over-dosing; compliance at home was good in the 108 subjects.
Genetic analysis
For SNP analysis, 7 ml of blood was collected 1 h before administration of aspirin on Day 1, and whole blood was stored at 41C. DNAs were purified from whole blood using a QIAamp DNA Blood Maxi kit (QIAGEN Inc., Tokyo, Japan). The genotypes of 24 SNPs in nine genes were determined.
The SNP regions were amplified by polymerase chain reaction (PCR). PCR was performed using a Takara PCR Amplification kit (Takara Bio Inc., Otsu, Japan). In 12 of the 24 SNPs, RFLP and direct sequencing were employed for genotyping. In the remaining SNPs, the genotype was determined by direct sequencing. PCR products were purified, and DNA sequences were determined using a Big Dye Terminator Cycle Sequencing kit and an ABI prism 3100 sequencer (Applied Biosystems, Foster City, CA, USA). Linkage disequilibrium was tested using Hitagene software (Hitachi Europe, Dublin, Ireland).
Statistical analysis
Two of the 110 subjects dropped out of this study; one could not consult this hospital for personal reasons, and the other developed acute gastritis related to this agent after the initial dosing. The frequency of alleles was analyzed in the 110 subjects, and the association with SNPs was analyzed in the 108 subjects excluding the above-mentioned two. All values were mean7s.d. unless otherwise specified. Significance among genotypes was assessed by Student's t-test or ANOVA. Post hoc pair-wise comparisons were performed with Tukey's HSD test. All analyses were performed with a commercially available statistical package (SAS ver.9.02, SAS Institute Inc., Cary, NC, USA). Null hypotheses were rejected at the Po0.05 level of significance.
Platelet aggregation Blood (13.5 ml) was collected from the subjects using a 21 G injection needle 1 h before administration of aspirin on Day 1 and 1 h after the final administration. Blood samples were divided into three 5-ml test tubes containing 0.5 ml of 3.8% sodium citrate solution (blood volume: 4.5 ml per test tube) for a platelet aggregation test. Immediately, blood was centrifuged at 80 g for 10 min to collect the superficial layer as platelet-rich plasma (PRP). In addition, the residual blood was centrifuged at 2000 g for 10 min to collect the superficial layer as platelet-poor plasma (PPP). The number of platelets in PRP was measured. When the platelet count exceeded 3 Â 10 5 /ml, plasma samples were diluted with PPP to prepare a concentration of 2 Â 10 5 /ml to 3 Â 10 5 /ml. Thus, PRP and PPP samples were used for a platelet aggregation test. These procedures were performed at room temperature. To stabilize platelet responsiveness, measurement was performed using these PRP samples between 1 and 2 h after blood collection. In each subject, permeability was measured using a platelet aggregometer (MCM hematracer 313-M, MC Medical Inc., Tokyo, Japan), regarding PRP permeability as 0% and PPP permeability as 100%. 26 PRP (200 ml) and a stirrer bar were placed in a cuvette for measurement, preincubated at 371C for 2 min, and mixed with 22 ml of collagen solution to prepare the final concentrations (before administration of aspirin: 0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 mg/ml; after administration of aspirin: 0.5, 1.0, 2.0, 4.0, 6.0 and 8.0 mg/ml). Platelet aggregation was measured twice. The mean maximum permeability over 10 min was regarded as the maximum aggregation (%).
Serum level of TXB 2
The serum level of TXB 2 (a stable metabolite of TXA 2 ) was measured by radioimmunoassay. Using a 5-ml vacuum tube for blood collection (VP-P050, Terumo Corporation, Tokyo, Japan), 4 ml of blood was collected 1 h before administration of aspirin on Day 1 and 1 h after the final administration. Whole blood was incubated at 371C for 1 h, and centrifuged at room temperature at 2000 g for 10 min to isolate serum. Serum samples were snap-frozen and stored at À201C or lower until measurement. According to the standard method, TXB 2 fractions were collected from 1.0 ml of serum, and the TXB 2 level was measured by the radioimmunoassay polyethyleneglycol (RIA-PEG) method (SRL Inc., Tokyo, Japan). As described in the protocol of a TXB 2 -[ 125 I]RIA kit (Parkin Elmer Japan Co. Ltd., Yokohama, Japan), 125 I was measured using an ARC-950 gamma counter (Aloka Co. Ltd., Tokyo, Japan). Using the calibration curve, the level of TXB 2 was calculated from the bound level. The detection limit was 150 pg/ml.
